Tagged with Generics

generics Chile is aiming to achieve complete bioequivalence of generics by the end of 2014. Chile’s Public Health Institute is leading the bioequivalence testing, aimed at regulating differences between generic and bioequivalent drugs. The recently appointed director of the Public Health Institute, Ricardo Fabrega, echoes the need for drastic change and…

Indian When Indian generics company Aurobindo established itself in Portugal in 2010, the affiliate was faced with some difficult choices. As the latest company to enter the Portuguese generic market, Aurobindo had the lowest prices in the market, which was not attractive to the pharmacy channel. Pedro Merlini, country manager of…

generics Raúl Díaz-Varela is the CEO of Kern Pharma and has served as president of Spain’s generics association AESEG since 2008. He speaks to us about the challenges facing generic companies, and Kern Pharma’s own strategies for growth through in-licensing and local partnerships in Europe and Latin America. What are your…

Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…

Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…

Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…

recession Dr. Heitor Costa, Executive Director at Apifarm, Portugal, discusses the country’s economic situation and the presence of international pharmaceutical companies despite the recession. He further discusses the current policy and influence of generics on the pharmaceutical industry, and why he feels investment in Portugal is so crucial at a time…

generics   “The IMS Health figures show around three to four percent growth in the marketplace,” remarks Raymund Azurin, chief executive of Zuellig Pharma Philippines, “but we are now at a point in time where the business models in this market are changing. The rise of generics and increasing government intervention…

Generics Kenneth Y Hartigan-Go, Acting Director General of the Food and Drug Administration Philippines (FDA) discusses the current state of regulations processes, strategies that the FDA are applying to the major challenges being presented, and further elaborates on the affect that the universal healthcare would have on the Filipino market.  One…

Generics Armando Esguerra, President of Chira Pharmaceuticals, Philippines, explains the concept of chirality, why it is relevant and extremely important in the pharmaceutical industry, and what have been the major challenges and successes of the company since its founding.    CHIRA Pharmaceuticals as a company was founded on the concept of…

Generics   Fransisco Velez, Founder and Director General of toLife, discusses the challenges facing generics companies in Portugal today, and his ambitions to further grow his company over the years to come.   What was the inspiration for creating toLife? I worked at Janssen Cilag for more than 20 years in…

Generics João Madeira, General Manager of Mylan Portugal provides an overview of the state of generics in Portugal today, discussing structural issues related to Portugal’s low generic medicines penetration, ways to better promote healthcare savings, and Mylan’s own contributions to ensuring a sustainable marketplace in Portugal. Prior to Mylan, you worked…